Iranian Society of Gynecology Oncology

Document Type : Original Research Article


Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran


Objective: In this placebo-controlled randomized clinical trial, we aimed to investigate the effect of low molecular weight heparin (LMWH) on the assisted reproductive technology (ART) success rate in women without thrombophilic disorder undergoing assisted reproductive technology.
Methods: The study population consisted of 276 patients referred to the infertility center at Shiraz University of Medical Sciences and who underwent in vitro fertilization (IVF) for the first time. Patients were randomly assigned into two groups (control group = 137 women who underwent IVF and received placebo; case group = 139 women who underwent IVF and received LMWH). The case group was treated with LMWH and the control group received placebo. Specifications for egg harvesting, processing sperm, the number of fertilized eggs and embryos, the number of frozen and transferred embryos, and the IVF outcome were assessed.
Results: The mean age of subjects was 32.59 ± 4.41 years old in the case group and 32.62 ± 5.18 in the control group (p = 0.955). The final outcome of IVF treatment in the control group was treatment failure (62%), clinical pregnancy (21.2%), chemical pregnancy (5.9%), and live birth (7.3%), while in the case group, it was treatment failure (48.2 %), clinical pregnancy (21.6%), chemical pregnancy (2.2%), and live births (28.1%). There was a significant difference in IVF outcome in the two groups (P < 0.001).
Conclusion: Given the significant difference in the number of live births and reduction of pregnancy complications in the LMWH group, it can be concluded that LMWH prophylaxis may be effective in ART success.


Main Subjects

1. Wilkes S, Chinn DJ, Murdoch A, Rubin G. Epidemiology and management of infertility: a population-based study in UK primary care. Fam Pract. 2009;26(4):269-74. [DOI:10.1093/fampra/cmp039] [DOI:10.1093/fampra/cmp029] [PMID]
2. Winarto H. Precision medicine: Leading medical research to change life results. J Nat Sci Biol Med. 2019;10(3):1.
3. Parsanezhad ME, Jahromi BN, Zare N, Keramati P, Khalili A, Parsa-Nezhad M. Epidemiology and etiology of infertility in Iran, systematic review and meta-analysis. J Womens Health. 2013;6(2). [DOI:10.4172/2325-9795.1000121]
4. Baroroh HN, Nugroho AE, Lukitaningsih E, Nurrochmad A. Immune-enhancing effect of bengkoang (Pachyrhizus erosus (L.) Urban) fiber fractions on mouse peritoneal macrophages, lymphocytes, and cytokines. J Nat Sci Biol Med. 2021;12(1):84. [DOI:10.4103/jnsbm.JNSBM_53_20]
5. Berker B, Taşkın S, Kahraman K, Taşkın EA, Atabekoğlu C, Sönmezer M. The role of low-molecular-weight heparin in recurrent implantation failure: a prospective, quasi-randomized, controlled study. Fertil Steril. 2011;95(8):2499-502. [DOI:10.1016/j.fertnstert.2010.12.033] [PMID]
6. Bohlmann MK. Effects and effectiveness of heparin in assisted reproduction. J Reprod Immunol. 2011;90(1):82-90. [DOI:10.1016/j.jri.2011.03.004] [PMID]
7. Fatemi H, Popovic-Todorovic B. Implantation in assisted reproduction: a look at endometrial receptivity. Reprod Biomed Online. 2013;27(5):530-8. [DOI:10.1016/j.rbmo.2013.05.018] [PMID]
8. Noci I, Milanini MN, Ruggiero M, Papini F, Fuzzi B, Artini PG. Effect of dalteparin sodium administration on IVF outcome in non-thrombophilic young women: a pilot study. Reprod Biomed Online. 2011;22(6):615-20. [DOI:10.1016/j.rbmo.2011.03.016] [PMID]
9. Patil HV, Patil VC. Comparative study of procalcitonin and C-reactive protein in patients with sepsis. J Nat Sci Biol Med. 2020;11(2):93. [DOI:10.4103/jnsbm.JNSBM_159_19]
10. Li X, Ma X. The role of heparin in sepsis: much more than just an anticoagulant. Br J Haematol. 2017;179(3):389-98. [DOI:10.1111/bjh.14885] [PMID]
11. Seshadri S, Sunkara S, Khalaf Y, El-Toukhy T, Hamoda H. Effect of heparin on the outcome of IVF treatment: a systematic review and meta-analysis. Reprod Biomed Online. 2012;25(6):572-84. [DOI:10.1016/j.rbmo.2012.08.007] [PMID]
12. Rokade A, Kshirsagar N, Laddad M. PAP Smear versus Colposcopy in Symptomatic Women and Women with Suspicious‑Looking Cervix. J Nat Sci Biol Med. 2021;12(2):145-. [DOI:10.4103/jnsbm.JNSBM_145_20]
13. Nasser NA, Baban RS, Al-Habib MF, Jameel RAA. The association between urinary placental protein 13 and soluble fms-like tyrosine kinase-1 in preeclamptic women in the third trimester of pregnancy. Baghdad j Biochem Appl Biol Sci. 2020;1(01):46-51. [DOI:10.47419/bjbabs.v1i01.31] [DOI:10.47419/bjbabs.v1i01.30]
14. Nelson SM, Greer IA. The potential role of heparin in assisted conception. Hum Reprod Update. 2008;14(6):623-45. [DOI:10.1093/humupd/dmn031] [PMID]
15. Nasser NA, Baban RS, Al-Habib MF, Jameel RAA. Serum placental growth factor (PLGF) and soluble fms-like tyrosine kinase-1 (sFLT-1) in preeclamptic women at their third trimester of pregnancy. Baghdad j Biochem Appl Biol Sci. 2020;1(01):39-45. [DOI:10.47419/bjbabs.v1i01.31] [DOI:10.47419/bjbabs.v1i01.30]
16. Siristatidis C, Dafopoulos K, Salamalekis G, Galazios G, Christoforidis N, Moustakarias T, et al. Administration of low-molecular-weight heparin in patients with two or more unsuccessful IVF/ICSI cycles: a multicenter cohort study. Gynecol Endocrinol. 2018;34(9):747-51. [DOI:10.1080/09513590.2018.1442426] [PMID]
17. Yang X-L, Chen F, Yang X-Y, Du G-H, Xu Y. Low molecular weight heparin does not reduce miscarriages in non-thrombophilic IVF/ICSI-treated women. Acta Obstet Gynecol Scand. 2019;98(1):131-2. [DOI:10.1111/aogs.13483] [PMID]
18. Skeith L, Carrier M, Kaaja R, Martinelli I, Petroff D, Schleußner E, et al. A meta-analysis of low-molecular-weight heparin to prevent pregnancy loss in women with inherited thrombophilia. Blood. 2016;127(13):1650-5. [DOI:10.1182/blood-2015-12-626739] [PMID]
19. Simcox LE, Ormesher L, Tower C, Greer IA. Thrombophilia and pregnancy complications. Int J Mol Sci. 2015;16(12):28418-28. [DOI:10.3390/ijms161226104] [PMID] [PMCID]
20. Allahbadia GN. Low-molecular-weight heparin (lmwh) in women with repeated implantation failure. Springer; 2012. [DOI:10.1007/s13224-012-0308-8] [PMID] [PMCID]
21. Safdarian L, Kheirollahi E, Alyasin A, Hossinei MA, Saeidi H. Therapeutic Effects of Heparin on Repeated Implantation Failures in IVF Cycles; A Randomized Clinical Trial. Journal of Reproduction & Infertility. 2008;9(3):246-55.
22. Qublan H, Amarin Z, Dabbas M, Farraj A-E, Beni-Merei Z, Al-Akash H, et al. Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: a prospective randomized placebo-controlled trial. Hum Fertil. 2008;11(4):246-53. [DOI:10.1080/14647270801995431] [PMID]
23. Singh N, Cheluvaraju R, Jain SK. A prospective randomized controlled trial showing efficacy of luteal phase low molecular weight heparin in fresh non-donor IVF/ICSI cycles in women with previous implantation failures. Int j Reprod Contracept Obstet Gynecol. 2019;8(11):4163-9. [DOI:10.18203/2320-1770.ijrcog20194839]
24. Awwad J, El Taha L, Ghunaim SS, Khalife D, Choucair F, Hamdar L, Ghazeeri GS. The Administration Of Luteal Phase Low Molecular Weight Heparin To Improve Live Births After Recurrent Implantation Failure: A Prospective Randomized Clinical Trial. Fertil Steril. 2021;116(3):e39. [DOI:10.1016/j.fertnstert.2021.07.115]
25. Jasirwan SO, Iffanolida PA, Santawi VPA, Friska D, Wiweko B. Relationship between morphology of tripronuclear embryo and chromosomal abnormalities potential in intracytoplasmic sperm injection cycles. J Nat Sci Biol Med. 2019;10(3):92.
26. Potdar N, Gelbaya TA, Konje JC, Nardo LG. Adjunct low-molecular-weight heparin to improve live birth rate after recurrent implantation failure: a systematic review and meta-analysis. Hum Reprod Update. 2013;19(6):674-84. [DOI:10.1093/humupd/dmt032] [PMID]